Losartan and Emotion Processing
Losartan Effects on the Extinction of Conditioned Fear in Humans
1 other identifier
interventional
70
1 country
1
Brief Summary
The aim of the study is to investigate the effect of losartan (50mg, single dose) on the extinction of conditioned fear
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable healthy
Started Jan 2018
Typical duration for not_applicable healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 4, 2018
CompletedStudy Start
First participant enrolled
January 4, 2018
CompletedFirst Posted
Study publicly available on registry
January 11, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedJune 6, 2018
June 1, 2018
10 months
January 4, 2018
June 4, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Losartan effects on neural activity during fear extinction
Neural activity will be measured by functional magnetic resonance imaging (fMRI). Effects of treatment will be evaluated by comparing extinction-related neural activity in the core extinction network (prefrontal cortex, limbic regions) between the active treatment and the placebo group.
1 hour
Secondary Outcomes (1)
Losartan effects on skin conductance responses during fear extinction
1 hour
Study Arms (2)
Losartan group
EXPERIMENTALPlacebo group
PLACEBO COMPARATORInterventions
administration of losartan (50 mg) (oral)
Eligibility Criteria
You may qualify if:
- Healthy subjects without past or current psychiatric or neurological disorders
You may not qualify if:
- history of head injury
- medical or psychiatric illness
- hypertension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Electronic Science and Technology of China
Chengdu, Sichuan, 611731, China
Related Publications (1)
Zhou F, Geng Y, Xin F, Li J, Feng P, Liu C, Zhao W, Feng T, Guastella AJ, Ebstein RP, Kendrick KM, Becker B. Human Extinction Learning Is Accelerated by an Angiotensin Antagonist via Ventromedial Prefrontal Cortex and Its Connections With Basolateral Amygdala. Biol Psychiatry. 2019 Dec 15;86(12):910-920. doi: 10.1016/j.biopsych.2019.07.007. Epub 2019 Jul 25.
PMID: 31471037DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Benjamin Becker, PhD
University of Electronic Science and Technology of China
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
January 4, 2018
First Posted
January 11, 2018
Study Start
January 4, 2018
Primary Completion
October 31, 2018
Study Completion
December 31, 2018
Last Updated
June 6, 2018
Record last verified: 2018-06
Data Sharing
- IPD Sharing
- Will not share